Mark Gottlieb
@Altium Capital Management Lp
Latest period2024 - Q3ReportedManaged Assets$339.708MTotal holdings77
Assets growth rate-99.86%Assets growth rate (2-Q avg)-51.42%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Altium Capital Management Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 77 positions.
Assets under management
The assets under management (AUM) of Altium Capital Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 339.708M in assets, with a quarterly growth rate of -99.86% and a 2-quarter average growth rate of -51.42%. The portfolio is managed by Mark Gottlieb, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
MMSIMerit Med Sys Inc
| 2.48% | $8.401M 85,000 shares@ $98.83 avg price | New Position |
RZLTRezolute Inc
| 2.43% | $8.245M 1.7M shares@ $4.85 avg price | |
PCVXVaxcyte Inc
| 2.43% | $8.227M 72,000 shares@ $114.27 avg price | New Position |
AVDLAvadel Pharmaceuticals Plc
| 2.36% | $8M 610,000 shares@ $13.12 avg price | |
VKTXViking Therapeutics Inc
| 2.35% | $7.977M 126,000 shares@ $63.31 avg price | Increased 3.28% |
CPRXCatalyst Pharmaceuticals Inc
| 2.26% | $7.654M 385,000 shares@ $19.88 avg price | Decreased -23% |
CTNMContineum Therapeutics Inc
| 2.08% | $7.065M 369,126 shares@ $19.15 avg price | Decreased -14.02% |
ARWRArrowhead Pharmaceuticals In
| 2.03% | $6.876M 355,000 shares@ $19.37 avg price | New Position |
SVRASavara Inc
| 1.97% | $6.678M 1.575M shares@ $4.24 avg price | Decreased -1.25% |
IRTCIrhythm Technologies Inc
| 1.88% | $6.385M 86,000 shares@ $74.24 avg price | New Position |